• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PXS
Click for more information
0.00% 8.5¢

PHARMAXIS LTD - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PXS Appendix 3B - Exercise of employee options11/08/15
PXS Investor presentation - August 201507/08/15
PXS Pharmaxis and Synairgen Announce Research CollaborationPRICE SENSITIVE05/08/15
PXS Change of Director's Interest Notice - McComas04/08/15
PXS Appendix 3B - exercise of employee options04/08/15
PXS Prposed Issue of Securities to Chief Executive Officer31/07/15
PXS Change of Director's Interest Notice31/07/15
PXS Appendix 3B - performance rights and employee share plan31/07/15
PXS Appendix 3B - exercise of employee options31/07/15
PXS Appendix 4C - quarterlyPRICE SENSITIVE31/07/15
PXS Quarterly Shareholder Update - June 201531/07/15
PXS Becoming a substantial holder01/07/15
PXS 29-06-2015 - Appendix 3B - exercise of employee options29/06/15
PXS Pharmaxis Share Trading Policy - updated June 201519/06/15
PXS Change in substantial holding18/06/15
PXS Ceasing to be a substantial holder from AEF15/06/15
PXS Change in substantial holding12/06/15
PXS Change in substantial holding09/06/15
PXS Becoming a substantial holder05/06/15
PXS Appendix 3B - exercise of employee options01/06/15
PXS Change of Director's Interest Notice27/05/15
PXS Investor Presentation19/05/15
PXS PXS Announces Completion of Restructuring and New FocusPRICE SENSITIVE19/05/15
PXS Appendix 3B - exercise of employee options18/05/15
PXS Boehringer Ingelheim acquires Pharmaxis phase 1 drugPRICE SENSITIVE18/05/15
PXS Appendix 3B - Exercise of employee options11/05/15
PXS Pharmaxis Signs Second Agreement with ChiesiPRICE SENSITIVE08/05/15
PXS Change in substantial holding from NAB24/04/15
PXS Appendix 3B - Exercise of employee options24/04/15
PXS Change in substantial holding from AEF - correction21/04/15
PXS Change in substantial holding from AEF21/04/15
PXS Appendix 4C - quarterly cash flowPRICE SENSITIVE17/04/15
PXS Shareholder Update - March Quarter 201517/04/15
PXS Interim Results of Phase 1 Clinical Trial for PXS4728APRICE SENSITIVE07/04/15
PXS Appendix 3B - exercise of employee options01/04/15
PXS Change in substantial holding19/03/15
PXS Appendix 3B - Exercise of employee options13/03/15
PXS Pharmaxis Signs with Boehringer Ingelheim for PXS4728APRICE SENSITIVE12/03/15
PXS Change of Director's Interest Notice - lapse of options26/02/15
PXS Appendix 3B - Exercise of employee options26/02/15
PXS Half Yearly Report and AccountsPRICE SENSITIVE26/02/15
PXS Appendix 4C - quarterlyPRICE SENSITIVE30/01/15
PXS Commencement of Phase 1 Clinical Trial for SSAO InhibitorPRICE SENSITIVE21/01/15
PXS Appendix 3B - Exercise of Employee Options12/01/15
PXS Commercialisation in US and NovaQuest Dispute SettledPRICE SENSITIVE24/12/14
PXS Appendix 3B - exercise of employee options02/12/14
PXS Results of Meeting28/11/14
PXS 2014 AGM Presentation27/11/14
PXS Chairman's Address to Shareholders27/11/14
PXS Appendix 3B - Exercise of Employee Options10/11/14
PXS Appendix 4C - quarterlyPRICE SENSITIVE30/10/14
PXS Quarterly Shareholder Letter - September 201430/10/14
PXS Phase 3 Clinical Trial in Cystic FibrosisPRICE SENSITIVE30/10/14
PXS Annual Report to shareholders24/10/14
PXS Notice of Annual General Meeting/Proxy Form24/10/14
PXS Appendix 3B - Exercise of Employee Options15/10/14
PXS Appendix 3B - Exercise of Employee Options08/09/14
PXS New data from B305 clinical trial presented at ERSPRICE SENSITIVE08/09/14
PXS Quarter 4 Shareholder Update28/08/14
PXS Preliminary Final Report, Financial and Directors' ReportPRICE SENSITIVE28/08/14
PXS SSAO Inhibitor Ready for the ClinicPRICE SENSITIVE28/08/14
PXS Pharmaxis Files Lawsuit Against NovaQuestPRICE SENSITIVE04/08/14
PXS Appendix 4C - quarterlyPRICE SENSITIVE30/07/14
PXS Update On Timing Of Pre-Clinical Partnering ProjectsPRICE SENSITIVE08/07/14
PXS Communication from Financier NovaQuestPRICE SENSITIVE08/07/14
PXS Trading HaltPRICE SENSITIVE04/07/14
PXS Bronchitol Shortlisted for Prestigious Orphan Drug Award30/06/14
PXS Bronchitol Clinic Experience Highlighted at European CF Meet18/06/14
PXSAppendix 4C - quarterlyPRICE SENSITIVE16/04/14
PXSPresentation - Quarterly Investor Briefing16/04/14
PXSPharmaxis Quarterly Investor Conference Call15/04/14
BLY +S&P DJ Indicies Announces March Quarterly Rebalance07/03/14
PXSAppendix 3B - exercise of employee options05/03/14
PXSInvestor Presentation - Quarterly Investor Briefing19/02/14
PXSHalf Yearly Report and AccountsPRICE SENSITIVE19/02/14
PXSPharmaxis Quarterly Investor Conference Call17/02/14
PXSAppendix 3B - Exercise of employee options14/02/14
PXSAppendix 4C - quarterlyPRICE SENSITIVE30/01/14
PXSAppendix 3B - Exercise of employee options12/12/13
PXSScottish Medicines Consortium Accepts Bronchitol for CF UsePRICE SENSITIVE10/12/13
PXSChange of Director's Interest Notice02/12/13
PXSAppendix 3B28/11/13
PXSResults of Meeting28/11/13
PXSCEO Presentation to AGM27/11/13
PXSChairman's Address to Shareholders27/11/13
PXSChange of Director's Interest Notice04/11/13
PXSAppendix 3B - option exercise04/11/13
PXSAppendix 3B - Employee restricted shares and options04/11/13
PXSPharmaxis Elects to Receive Full NovaQuest InvestmentPRICE SENSITIVE30/10/13
PXSChange in substantial holding23/10/13
PXSChange in substantial holding22/10/13
PXSNotice of Annual General Meeting/Proxy Form21/10/13
PXSPharmaxis Quarterly Investor Briefing16/10/13
PXSAppendix 4C - quarterlyPRICE SENSITIVE16/10/13
PXSPHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL15/10/13
PXS2013 Annual Report to Shareholders25/09/13
PXSFinal Director's Interest Notice - R van den Broek19/09/13
PXSFinal Director's Interest Notice - J Villiger19/09/13
PXSPharmaxis Announces Two Board Retirements19/09/13
PRX +S&P DJ Indices Announces September Quarterly Rebalance06/09/13
PXS Appendix 3B - Exercise of employee options
11/08/15
PXS Investor presentation - August 2015
07/08/15
PXS Pharmaxis and Synairgen Announce Research Collaboration
05/08/15PRICE SENSITIVE
PXS Change of Director's Interest Notice - McComas
04/08/15
PXS Appendix 3B - exercise of employee options
04/08/15
PXS Prposed Issue of Securities to Chief Executive Officer
31/07/15
PXS Change of Director's Interest Notice
31/07/15
PXS Appendix 3B - performance rights and employee share plan
31/07/15
PXS Appendix 3B - exercise of employee options
31/07/15
PXS Appendix 4C - quarterly
31/07/15PRICE SENSITIVE
PXS Quarterly Shareholder Update - June 2015
31/07/15
PXS Becoming a substantial holder
01/07/15
PXS 29-06-2015 - Appendix 3B - exercise of employee options
29/06/15
PXS Pharmaxis Share Trading Policy - updated June 2015
19/06/15
PXS Change in substantial holding
18/06/15
PXS Ceasing to be a substantial holder from AEF
15/06/15
PXS Change in substantial holding
12/06/15
PXS Change in substantial holding
09/06/15
PXS Becoming a substantial holder
05/06/15
PXS Appendix 3B - exercise of employee options
01/06/15
PXS Change of Director's Interest Notice
27/05/15
PXS Investor Presentation
19/05/15
PXS PXS Announces Completion of Restructuring and New Focus
19/05/15PRICE SENSITIVE
PXS Appendix 3B - exercise of employee options
18/05/15
PXS Boehringer Ingelheim acquires Pharmaxis phase 1 drug
18/05/15PRICE SENSITIVE
PXS Appendix 3B - Exercise of employee options
11/05/15
PXS Pharmaxis Signs Second Agreement with Chiesi
08/05/15PRICE SENSITIVE
PXS Change in substantial holding from NAB
24/04/15
PXS Appendix 3B - Exercise of employee options
24/04/15
PXS Change in substantial holding from AEF - correction
21/04/15
PXS Change in substantial holding from AEF
21/04/15
PXS Appendix 4C - quarterly cash flow
17/04/15PRICE SENSITIVE
PXS Shareholder Update - March Quarter 2015
17/04/15
PXS Interim Results of Phase 1 Clinical Trial for PXS4728A
07/04/15PRICE SENSITIVE
PXS Appendix 3B - exercise of employee options
01/04/15
PXS Change in substantial holding
19/03/15
PXS Appendix 3B - Exercise of employee options
13/03/15
PXS Pharmaxis Signs with Boehringer Ingelheim for PXS4728A
12/03/15PRICE SENSITIVE
PXS Change of Director's Interest Notice - lapse of options
26/02/15
PXS Appendix 3B - Exercise of employee options
26/02/15
PXS Half Yearly Report and Accounts
26/02/15PRICE SENSITIVE
PXS Appendix 4C - quarterly
30/01/15PRICE SENSITIVE
PXS Commencement of Phase 1 Clinical Trial for SSAO Inhibitor
21/01/15PRICE SENSITIVE
PXS Appendix 3B - Exercise of Employee Options
12/01/15
PXS Commercialisation in US and NovaQuest Dispute Settled
24/12/14PRICE SENSITIVE
PXS Appendix 3B - exercise of employee options
02/12/14
PXS Results of Meeting
28/11/14
PXS 2014 AGM Presentation
27/11/14
PXS Chairman's Address to Shareholders
27/11/14
PXS Appendix 3B - Exercise of Employee Options
10/11/14
PXS Appendix 4C - quarterly
30/10/14PRICE SENSITIVE
PXS Quarterly Shareholder Letter - September 2014
30/10/14
PXS Phase 3 Clinical Trial in Cystic Fibrosis
30/10/14PRICE SENSITIVE
PXS Annual Report to shareholders
24/10/14
PXS Notice of Annual General Meeting/Proxy Form
24/10/14
PXS Appendix 3B - Exercise of Employee Options
15/10/14
PXS Appendix 3B - Exercise of Employee Options
08/09/14
PXS New data from B305 clinical trial presented at ERS
08/09/14PRICE SENSITIVE
PXS Quarter 4 Shareholder Update
28/08/14
PXS Preliminary Final Report, Financial and Directors' Report
28/08/14PRICE SENSITIVE
PXS SSAO Inhibitor Ready for the Clinic
28/08/14PRICE SENSITIVE
PXS Pharmaxis Files Lawsuit Against NovaQuest
04/08/14PRICE SENSITIVE
PXS Appendix 4C - quarterly
30/07/14PRICE SENSITIVE
PXS Update On Timing Of Pre-Clinical Partnering Projects
08/07/14PRICE SENSITIVE
PXS Communication from Financier NovaQuest
08/07/14PRICE SENSITIVE
PXS Trading Halt
04/07/14PRICE SENSITIVE
PXS Bronchitol Shortlisted for Prestigious Orphan Drug Award
30/06/14
PXS Bronchitol Clinic Experience Highlighted at European CF Meet
18/06/14
PXSAppendix 4C - quarterly
16/04/14PRICE SENSITIVE
PXSPresentation - Quarterly Investor Briefing
16/04/14
PXSPharmaxis Quarterly Investor Conference Call
15/04/14
BLY +S&P DJ Indicies Announces March Quarterly Rebalance
07/03/14
PXSAppendix 3B - exercise of employee options
05/03/14
PXSInvestor Presentation - Quarterly Investor Briefing
19/02/14
PXSHalf Yearly Report and Accounts
19/02/14PRICE SENSITIVE
PXSPharmaxis Quarterly Investor Conference Call
17/02/14
PXSAppendix 3B - Exercise of employee options
14/02/14
PXSAppendix 4C - quarterly
30/01/14PRICE SENSITIVE
PXSAppendix 3B - Exercise of employee options
12/12/13
PXSScottish Medicines Consortium Accepts Bronchitol for CF Use
10/12/13PRICE SENSITIVE
PXSChange of Director's Interest Notice
02/12/13
PXSAppendix 3B
28/11/13
PXSResults of Meeting
28/11/13
PXSCEO Presentation to AGM
27/11/13
PXSChairman's Address to Shareholders
27/11/13
PXSChange of Director's Interest Notice
04/11/13
PXSAppendix 3B - option exercise
04/11/13
PXSAppendix 3B - Employee restricted shares and options
04/11/13
PXSPharmaxis Elects to Receive Full NovaQuest Investment
30/10/13PRICE SENSITIVE
PXSChange in substantial holding
23/10/13
PXSChange in substantial holding
22/10/13
PXSNotice of Annual General Meeting/Proxy Form
21/10/13
PXSPharmaxis Quarterly Investor Briefing
16/10/13
PXSAppendix 4C - quarterly
16/10/13PRICE SENSITIVE
PXSPHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL
15/10/13
PXS2013 Annual Report to Shareholders
25/09/13
PXSFinal Director's Interest Notice - R van den Broek
19/09/13
PXSFinal Director's Interest Notice - J Villiger
19/09/13
PXSPharmaxis Announces Two Board Retirements
19/09/13
PRX +S&P DJ Indices Announces September Quarterly Rebalance
06/09/13
refresh Created with Sketch. REFRESH
 

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Chaos reigns markets – so let's take stock of where we're at ahead of December For many people, it feels like the world has been getting crazier each year since 2020 (or 2016.) It's likely to continue
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.